Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Leukemia 1Hematologic Neoplasms 1Blast Crisis 1

Interventions

Cyclophosphamide 64Peripheral Blood Stem Cell Transplantation 58fludarabine phosphate 55Busulfan 44Tacrolimus 39Methotrexate 38Cytarabine 37Filgrastim 34Mycophenolic Acid 33Cyclosporine 33Antilymphocyte Serum 32Whole-Body Irradiation 28Radiotherapy 25Methylprednisolone 22Imatinib Mesylate 22Etoposide 22Melphalan 18Cord Blood Stem Cell Transplantation 18Flow Cytometry 14Thiotepa 12Dasatinib 12Therapeutics 11sargramostim 10merphos 10fludarabine 10Sirolimus 10Granulocyte Colony-Stimulating Factor 10nilotinib 9Prednisone 9Carboplatin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Blast Crisis × STA 9090 × Other hematologic neoplasm × Clear all
NCT00964873 2014-09-18

A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia

Synta Pharmaceuticals Corp.

Phase 1 Completed
29 enrolled
LymphoidOther hematologic neoplasm

Blast Crisis, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡